HMGB1 and epilepsy: This molecule could be targeted by specific therapies, since monoclonal antibodies against HMGB1 demonstrated to be effective in refractory epilepsy (29) and glycyrrhizin, an additional HMGB1 inhibitor, was able to protect from neuronal inflammation in a mouse model of autoimmune encephalomyelitis (30).